Development of a highly-efficient erythrocyte-drug covalent conjugation platform and its use in treating thrombotic disorders  

作　　者：Yanjie Huang Xiaoqian Nie Xuewen Liu Yuehua Liu Huifei Yu Xiaofei Gao 

机构地区：[1]School of Basic Medical Sciences,Fudan University,Shanghai,China [2]Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China [3]Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China [4]Institute of Basic Medical Sciences,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China [5]College of Life Sciences,Zhejiang University,Hangzhou,Zhejiang,China [6]Westlake Therapeutics,Inc.,Hangzhou,Zhejiang,China

出　　处：《Cell Research》2023年第11期887-890,共4页细胞研究（英文版）

基　　金：supported in part by grants from the National Natural Science Foundation of China (81973993);Zhejiang Provincial Natural Science Foundation of China (LR20C070001).

摘　　要：Dear Editor,Red blood cells(RBCs)are the most abundant cells in the human body.RBCs have been widely investigated as in vivo drug delivery systems due to their unique biological properties.

关 键 词：properties. DRUG abundant 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]